Elizabeth A. Atchison
Research Subjects
Elizabeth A. Atchison has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Sophie J. Bakri
Department of Ophthalmology (S.J.B.), Mayo Clinic, Rochester, Minnesota, USA
3 shared publications - Andrew J. Barkmeier
Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota
2 shared publications Adi Gidron
1 shared publication- Ahmed F. Omar
Department of Ophthalmology and Visual Sciences, Case Western Reserve University and University Hospitals Eye Institute, Cleveland, OH; and
1 shared publication - Aimee J. Szewka
Department of Ophthalmology, Rush Medical College, Rush University, Chicago, IL, USA
1 shared publication Alfred Rademaker
1 shared publication
Latest Publications
- 21 May 2021
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 6 (5) , 409-411
Unilateral Retinal Vasculitis as the Presenting Manifestation of Parry-Romberg Syndrome (Progressive Hemifacial Atrophy)
Purpose: This work aims to present a case of retinal vasculitis associated with Parry-Romberg syndrome. Method: A case report is presented. Results: A 17-year-old man with new floaters was found to have 20/40 vision with 1+ vitreous cell and retinal vasculitis in the right eye only. Workup for infectious etiologies did not reveal an explanation for the retinal vasculitis. However, magnetic resonance imaging of the head showed areas of linear band-like atrophy and scarring of the scalp and soft tissues as well as areas of gliosis and encephalomalacia in the subcortical white matter, all of which were consistent with Parry-Romberg syndrome. The patient was prescribed oral steroids and methotrexate, and the retinal vasculitis improved. Conclusions: Parry-Romberg syndrome is a rarely reported cause of retinal vasculitis and should be kept in the differential for retinal vasculitis.
- 21 May 2021
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 6 (5) , 409-411
Unilateral Retinal Vasculitis as the Presenting Manifestation of Parry-Romberg Syndrome (Progressive Hemifacial Atrophy)
Purpose: This work aims to present a case of retinal vasculitis associated with Parry-Romberg syndrome. Method: A case report is presented. Results: A 17-year-old man with new floaters was found to have 20/40 vision with 1+ vitreous cell and retinal vasculitis in the right eye only. Workup for infectious etiologies did not reveal an explanation for the retinal vasculitis. However, magnetic resonance imaging of the head showed areas of linear band-like atrophy and scarring of the scalp and soft tissues as well as areas of gliosis and encephalomalacia in the subcortical white matter, all of which were consistent with Parry-Romberg syndrome. The patient was prescribed oral steroids and methotrexate, and the retinal vasculitis improved. Conclusions: Parry-Romberg syndrome is a rarely reported cause of retinal vasculitis and should be kept in the differential for retinal vasculitis.
- 1 January 2021
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 15 (1) , 81-83
LOCALIZATION OF MACULAR CRYSTALS ASSOCIATED WITH CHRONIC RETINAL DETACHMENT TO THE POSTERIOR HYALOID USING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY
Purpose: To present a case of crystalline retinopathy associated with chronic retinal detachment and localize the macular crystals using spectral domain optical coherence tomography. Methods: Case Report. Results: A 37-year-old man with previously treated chronic retinal detachment presented with normal vision and crystalline maculopathy. Spectral domain optical coherence tomography localized the macular crystals to the posterior hyaloid membrane and on the internal limiting membrane, but not within the retina. Conclusion: The macular crystals in crystalline retinopathy associated with chronic retinal detachment most likely originate in the subretinal space beneath the detached retina, migrate through the retinal break into the vitreous cavity, and lodge on the surface of the internal limiting membrane. When the posterior hyaloid membrane separates, the crystals, which are attached to the posterior hyaloid membrane, elevate from the retina.
- 1 January 2021
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 15 (1) , 81-83
LOCALIZATION OF MACULAR CRYSTALS ASSOCIATED WITH CHRONIC RETINAL DETACHMENT TO THE POSTERIOR HYALOID USING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY
Purpose: To present a case of crystalline retinopathy associated with chronic retinal detachment and localize the macular crystals using spectral domain optical coherence tomography. Methods: Case Report. Results: A 37-year-old man with previously treated chronic retinal detachment presented with normal vision and crystalline maculopathy. Spectral domain optical coherence tomography localized the macular crystals to the posterior hyaloid membrane and on the internal limiting membrane, but not within the retina. Conclusion: The macular crystals in crystalline retinopathy associated with chronic retinal detachment most likely originate in the subretinal space beneath the detached retina, migrate through the retinal break into the vitreous cavity, and lodge on the surface of the internal limiting membrane. When the posterior hyaloid membrane separates, the crystals, which are attached to the posterior hyaloid membrane, elevate from the retina.
- 20 August 2019
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 3 (5) , 324-327
Elimination of Steroid Drops After Vitreoretinal Surgery
Purpose: The objective of this study was to compare intraocular pressure (IOP) and inflammatory outcomes between patients receiving a single subconjunctival triamcinolone acetonide injection at the end of surgery and those receiving subconjunctival dexamethasone at the end of surgery plus a traditional topical steroid drop taper. Methods: A retrospective consecutive case series compared patients operated on by 2 surgeons, both utilizing 500 mL BSS-PLUS (balanced salt solution with bicarbonate, dextrose, and glutathione; Alcon Laboratories, Inc) infusion solution containing 10 mg dexamethasone, which is added to the solution in the operating room or at the pharmacy. However, one surgeon utilized a single 4 mg triamcinolone acetonide subconjunctival injection at the end of surgery, without additional steroid drops (intervention group), and the other utilized subconjunctival dexamethasone plus a traditional topical steroid taper over a period of 4 to 6 weeks (control group). Results: There were 161 surgeries in the intervention group and 163 in the control group. No statistically significant differences were found in the usage rate of additional IOP-lowering drops, IOP > 29 mmHg, or IOP increase ≥ 10 mmHg over baseline during the follow-up period. Inflammatory complications were rare in both groups. Five percent of those in the intervention group received supplemental topical steroid drops postoperatively. Conclusions: A single subconjunctival triamcinolone acetonide injection at the end of surgery may represent a reasonable alternative to requiring patients to use a steroid drop taper following vitreoretinal surgery.
- 20 August 2019
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 3 (5) , 324-327
Elimination of Steroid Drops After Vitreoretinal Surgery
Purpose: The objective of this study was to compare intraocular pressure (IOP) and inflammatory outcomes between patients receiving a single subconjunctival triamcinolone acetonide injection at the end of surgery and those receiving subconjunctival dexamethasone at the end of surgery plus a traditional topical steroid drop taper. Methods: A retrospective consecutive case series compared patients operated on by 2 surgeons, both utilizing 500 mL BSS-PLUS (balanced salt solution with bicarbonate, dextrose, and glutathione; Alcon Laboratories, Inc) infusion solution containing 10 mg dexamethasone, which is added to the solution in the operating room or at the pharmacy. However, one surgeon utilized a single 4 mg triamcinolone acetonide subconjunctival injection at the end of surgery, without additional steroid drops (intervention group), and the other utilized subconjunctival dexamethasone plus a traditional topical steroid taper over a period of 4 to 6 weeks (control group). Results: There were 161 surgeries in the intervention group and 163 in the control group. No statistically significant differences were found in the usage rate of additional IOP-lowering drops, IOP > 29 mmHg, or IOP increase ≥ 10 mmHg over baseline during the follow-up period. Inflammatory complications were rare in both groups. Five percent of those in the intervention group received supplemental topical steroid drops postoperatively. Conclusions: A single subconjunctival triamcinolone acetonide injection at the end of surgery may represent a reasonable alternative to requiring patients to use a steroid drop taper following vitreoretinal surgery.
- 1 May 2018
- Published by Elsevier in Ophthalmology
- Vol. 125 (5) , 676-682
The Real-World Effect of Intravitreous Anti–Vascular Endothelial Growth Factor Drugs on Intraocular Pressure
- 1 May 2018
- Published by Elsevier in Ophthalmology
- Vol. 125 (5) , 676-682
The Real-World Effect of Intravitreous Anti–Vascular Endothelial Growth Factor Drugs on Intraocular Pressure
- 1 January 2018
- Published by Elsevier in Survey of Ophthalmology
- Vol. 63 (1) , 1-8
Central serous chorioretinopathy and glucocorticoids: an update on evidence for association
- 1 January 2018
- Published by Elsevier in Survey of Ophthalmology
- Vol. 63 (1) , 1-8
Central serous chorioretinopathy and glucocorticoids: an update on evidence for association
- Open Access
- 10 August 2017
- Published by Springer Nature in Current Ophthalmology Reports
- Vol. 5 (3) , 270
Erratum to: The Role of Systemic Risk Factors in Diabetic Retinopathy
- 10 August 2017
- Published by Springer Nature in Current Ophthalmology Reports
- Vol. 5 (3) , 270
Open AccessErratum to: The Role of Systemic Risk Factors in Diabetic Retinopathy
- 1 July 2017
- Published by Wolters Kluwer Health in Retina
- Vol. 37 (7) , 1371-1376
OUTCOMES OF AN INTRAVITREAL INJECTION CLINIC
Purpose: To examine the safety outcomes of an intravitreal injection-only clinic where patients needing long-term anti-vascular endothelial growth factor therapy are treated with injections at a predetermined interval for a set number of injections without an accompanying clinic visit. Methods: This is a retrospective chart review of all patients with exudative macular degeneration treated in an intravitreal injection clinic over a 4-year period. Data on the outcome measures of interest were gathered from electronic medical records. Results: There were 556 patients who received 4,386 injections in the injection-only clinic in a total of 1,524 injection cycles. One hundred six cycles were interrupted. The most common causes for interruption were decreased vision in the injected eye (32), decreased vision in the fellow eye (23), flashing lights (6), pain (5), and irritation in the noninjected eye (2). Of patients who had interruption of the cycle, 32 had a new diagnosis (6 corneal abrasions, 6 exudative age-related macular degeneration in fellow eye). There were six instances of conversion to exudative age-related macular degeneration found in the other eye at a routine follow-up visit following the injection clinic. Conclusion: An injection-only clinic may provide a reasonable approach to streamline retina practices to ensure that patients receive timely injections.
- 1 July 2017
- Published by Wolters Kluwer Health in Retina
- Vol. 37 (7) , 1371-1376
OUTCOMES OF AN INTRAVITREAL INJECTION CLINIC
Purpose: To examine the safety outcomes of an intravitreal injection-only clinic where patients needing long-term anti-vascular endothelial growth factor therapy are treated with injections at a predetermined interval for a set number of injections without an accompanying clinic visit. Methods: This is a retrospective chart review of all patients with exudative macular degeneration treated in an intravitreal injection clinic over a 4-year period. Data on the outcome measures of interest were gathered from electronic medical records. Results: There were 556 patients who received 4,386 injections in the injection-only clinic in a total of 1,524 injection cycles. One hundred six cycles were interrupted. The most common causes for interruption were decreased vision in the injected eye (32), decreased vision in the fellow eye (23), flashing lights (6), pain (5), and irritation in the noninjected eye (2). Of patients who had interruption of the cycle, 32 had a new diagnosis (6 corneal abrasions, 6 exudative age-related macular degeneration in fellow eye). There were six instances of conversion to exudative age-related macular degeneration found in the other eye at a routine follow-up visit following the injection clinic. Conclusion: An injection-only clinic may provide a reasonable approach to streamline retina practices to ensure that patients receive timely injections.
- 9 December 2016
- Published by Taylor & Francis in Seminars in Ophthalmology
- Vol. 33 (3) , 308-312
Intraocular Pressure after Intravitreal Triesence Injection
Purpose: Elevated intraocular pressure (IOP) is a frequent adverse event associated with intravitreal triamcinolone acetate injection. The incidence of elevated IOP with preserved forms of triamcinolone has been studied but the effect of preservative-free formulations has not been clinically evaluated. Design: A retrospective, observational clinical study. Methods: For patients undergoing intravitreal injections over the study period, age, sex, history of glaucoma or ocular hypertension were recorded. For each injection, preinjection IOP, maximum IOP (IOPmax), dose, and indication for injection were noted for both eyes. Results: Fourteen patients received 72 injections in 18 eyes. The mean baseline IOP was 15.4 mm Hg; the mean IOPmax was 19.8 mm Hg (Pmax. Conclusions: Eyes should be monitored for IOP rises after preservative-free triamcinolone acetonide injections.
- 9 December 2016
- Published by Taylor & Francis in Seminars in Ophthalmology
- Vol. 33 (3) , 308-312
Intraocular Pressure after Intravitreal Triesence Injection
Purpose: Elevated intraocular pressure (IOP) is a frequent adverse event associated with intravitreal triamcinolone acetate injection. The incidence of elevated IOP with preserved forms of triamcinolone has been studied but the effect of preservative-free formulations has not been clinically evaluated. Design: A retrospective, observational clinical study. Methods: For patients undergoing intravitreal injections over the study period, age, sex, history of glaucoma or ocular hypertension were recorded. For each injection, preinjection IOP, maximum IOP (IOPmax), dose, and indication for injection were noted for both eyes. Results: Fourteen patients received 72 injections in 18 eyes. The mean baseline IOP was 15.4 mm Hg; the mean IOPmax was 19.8 mm Hg (Pmax. Conclusions: Eyes should be monitored for IOP rises after preservative-free triamcinolone acetonide injections.
- Open Access
- 25 March 2016
- Published by Springer Nature in Current Ophthalmology Reports
- Vol. 4 (2) , 84-89
The Role of Systemic Risk Factors in Diabetic Retinopathy
Diabetic retinopathy is an increasingly common medical issue in the United States. The risk of developing the disease or having the disease progress is caused by many systemic health factors. This article examines the existing literature on the links between glycemic control, arterial hypertension, high cholesterol and hyperlipidemia, obesity, inflammatory markers, sleep-disordered breathing, and exercise with risk of diabetic retinopathy development and prevention. The literature shows benefit for good glycemic and blood pressure control. The effects of cholesterol, and lipid control, inflammatory markers, sleep-disordered breathing, obesity, and exercise are less well established.
- 25 March 2016
- Published by Springer Nature in Current Ophthalmology Reports
- Vol. 4 (2) , 84-89
Open AccessThe Role of Systemic Risk Factors in Diabetic Retinopathy
Diabetic retinopathy is an increasingly common medical issue in the United States. The risk of developing the disease or having the disease progress is caused by many systemic health factors. This article examines the existing literature on the links between glycemic control, arterial hypertension, high cholesterol and hyperlipidemia, obesity, inflammatory markers, sleep-disordered breathing, and exercise with risk of diabetic retinopathy development and prevention. The literature shows benefit for good glycemic and blood pressure control. The effects of cholesterol, and lipid control, inflammatory markers, sleep-disordered breathing, obesity, and exercise are less well established.
- 1 January 2016
- Published by Elsevier in Ophthalmology
- Vol. 123 (1) , 209-213
Expression of Vascular Endothelial Growth Factor Receptors in Benign Vascular Lesions of the Orbit
- 1 January 2016
- Published by Elsevier in Ophthalmology
- Vol. 123 (1) , 209-213
Expression of Vascular Endothelial Growth Factor Receptors in Benign Vascular Lesions of the Orbit